Larimar Therapeutics, Inc.
NASDAQ:LRMRBiotechnology
+$0.04 today
- Market cap
- $337.45M
- Beta
- 0.82
- P/E (TTM)
- -1.8
- EPS (TTM)
- -$1.95
Volume 1.41M
Average 1.73M
LRMR Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
Larimar Therapeutics, Inc.NASDAQ: LRMR
Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026
Selling, general & admin growth accelerates
Q1 FY2026 selling, general & admin of $6.09M rose 31.3% year over year, ahead of the +7.4% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 31.0% from the prior quarter. Over 3 fiscal years it compounded at +14.2% a year.
Context
- Selling, general & admin increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether selling, general & admin reaches the consensus estimate from 6 analysts of $0 (-100.0%) for the fiscal year ending Dec 2026, a slowdown from the +3.8% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $6.09M+31.0% QoQ
- Last fiscal yearDec 2025
- $18.27M+3.8% YoY
- LTMMar 2026
- $19.82M+7.4% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +31.3% | -100.0% | -131.3 pp |
| 1 year | +3.8% | -100.0% | -103.8 pp |
| 3-year CAGR | +14.2% | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 18.27M USD
- Year-over-year change
- +3.8%
- 4-year CAGR
- +10.9%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 18.27M | +3.8% |
| FY2024 | 2024-12-31 | 17.61M | +25.0% |
| FY2023 | 2023-12-31 | 14.09M | +14.8% |
| FY2022 | 2022-12-31 | 12.28M | +1.7% |
| FY2021 | 2021-12-31 | 12.07M | — |
Selling, General & Admin vs competitors
How LRMR compares with its peers on the latest reported figures
- Peers report in different currencies, so selling, general & admin is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +7.4% is the 5th highest of 11, against a peer median of +1.8%.
- Over three fiscal years its annual growth of +14.2% compares with a peer median of +18.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $99.54M USD | -33.2% | -27.7% | 46.3% | |
| LTM Mar 2026 | $38.19M USD | +65.9% | +17.2% | — | |
| LTM Mar 2026 | $37.43M USD | +18.7% | +65.2% | — | |
LXEOLexeo Therapeutics, Inc. Common Stock | LTM Mar 2026 | $35.46M USD | -13.0% | +55.9% | — |
ENGNenGene Holdings Inc. | LTM Apr 2026 | $35.41M USD | +41.6% | +106.4% | — |
| LTM Mar 2026 | $32.75M USD | -0.8% | +0.8% | — | |
| LTM Mar 2026 | $30.49M USD | -15.8% | +18.8% | 793.5% | |
| LTM Mar 2026 | $30.16M USD | +39.3% | +17.9% | 83769.4% | |
| LTM Mar 2026 | $21.89M USD | -3.6% | +59.0% | — | |
| LTM Mar 2026 | $19.82M USD | +7.4% | +14.2% | — | |
| LTM Mar 2026 | CHF 11.38M CHF | +4.4% | +6.7% | 307.5% | |
| Peer median (excluding LRMR) | — | +1.8% | +18.4% | 550.5% | |
Competitors are the stored peer set for LRMR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 38.4M | 24.25M | 27.67M | 73.28M | 154.22M |
| Selling, General & Admin | 12.07M | 12.28M | 14.09M | 17.61M | 18.27M |
| Operating Expenses | 50.47M | 36.53M | 41.76M | 90.89M | 172.5M |
| Depreciation & Amortization | 326K | 318K | 311K | 318K | 350K |
| EBITDA | (50.31M) | (35.04M) | (36.64M) | (80.29M) | (165.32M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (50.47M) | (36.53M) | (41.76M) | (90.89M) | (172.5M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (171K) | 1.17M | 4.81M | 10.29M | 6.82M |
| Income Before Tax | (50.64M) | (35.36M) | (36.95M) | (80.6M) | (165.67M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (50.64M) | (35.36M) | (36.95M) | (80.6M) | (165.67M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (2.93) | (1.33) | (0.84) | (1.32) | (2.27) |
| EPS (Diluted) | (2.93) | (1.33) | (0.84) | (1.32) | (2.27) |
| Weighted Avg Shares | 17.16M | 25.76M | 43.9M | 61.26M | 72.95M |
| Weighted Avg Shares (Diluted) | 17.16M | 25.76M | 43.9M | 61.26M | 72.95M |
Larimar Therapeutics, Inc.
NASDAQ:LRMR
Intrinsic Alpha fair value
Locked
Current Price
$3.23
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.